



NDA 201,688/S-002

SUPPLEMENT APPROVAL

Novartis Pharmaceuticals Corporation
Attention: Mercy Abraham, PharmD
Sr. Global Program Regulatory Manager, Drug Regulatory Affairs
One Health Plaza
East Hanover, NJ 07936-1080

Dear Dr. Abraham:

Please refer to your Supplemental New Drug Application (sNDA) dated October 25, 2013, received October 25, 2013, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for TOBI Podhaler (tobramycin inhalation powder) for oral inhalation, 28 mg.

We acknowledge receipt of your amendment dated April 11, 2014.

This “Changes Being Effected” supplemental new drug application provides for the addition of a **Post-Marketing Experience** subsection (6.2) to the **ADVERSE REACTIONS** section (6.0) to add aphonia as a nervous system disorder. In addition, the word “intravenous” has been added to the **DRUG INTERACTIONS** section and **Patient Information** section in order to clarify that TOBI Podhaler should not be administered concomitantly with intravenous mannitol.

APPROVAL & LABELING

We have completed our review of this supplemental application as amended and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at:

<http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>.

Content of labeling must be identical to the enclosed labeling (text for the package insert, text for the patient package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at:

<http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, MS, Senior Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Sumathi Nambiar, MD, MPH
Director
Division of Anti-Infective Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

SUMATHI NAMBIAR
04/25/2014